0.36
+4.35%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About New Ray Medicine International Holding
Its shares trade on HKEX under the ticker 6108.HK. It has been listed since 25 October 2013. In the fiscal year to 31 December 2025, it reported revenue of HK$130.4m and a net loss of HK$20.1m. At that date it held total assets of HK$436.5m and shareholders' equity of HK$424.2m.
New Ray Medicine International Holding Ltd. is an investment company, which engages in the distribution and trading of pharmaceutical products. The company is headquartered in Hangzhou, Zhejiang. The company went IPO on 2013-10-25. The firm operates its business through four segments. The Injection Drugs segment is engaged in the trading of injection drugs. The Capsule and Granule Drugs segment is engaged in the trading of capsule and granule drugs. The Tablet Drugs segment is engaged in the trading of tablet drugs. The Others segment is engaged in the trading of miscellaneous types of goods and drugs.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 25 Oct 2013
- Employees
- 25
- Website
- newraymedicine.com ↗
Leadership
Pay as last reported
- Ms. Qiuqin WangExecutive Chairman of the Board, Chief Executive Officer, since 2018
- Mr. Xueping ChuExecutive Director, since 2021
- Ms. Wan ZhouExecutive Director, since 2023
- Linxing HeDirector of subsidiaries of the Company
- Mr. Yat Sing NgCompany Secretary
- Chi Kin LeungNon-Executive Independent Director
- Ms. Sin Ming LiNon-Executive Independent Director
- Mr. Lai Yin SyIndependent Non-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- New Ray Medicine's Injection Drugs segment distributes high-demand pharmaceuticals in Hangzhou.
- The Capsule and Granule Drugs segment serves regional markets with specialized drug formulations.
- The Tablet Drugs segment offers a diverse range of pharmaceutical products to healthcare providers.
Weaknesses
- The company's small employee count of 25 limits operational capacity in Hangzhou.
- Limited business segments restrict market reach across China's pharmaceutical industry.
- The Others segment's miscellaneous goods trading lacks focus on core pharmaceutical products.
Opportunities
- Expanding the Injection Drugs segment into Zhejiang province could increase market share.
- Growing demand for capsule and granule drugs in China presents new revenue streams.
- The Tablet Drugs segment can leverage China's aging population for increased sales.
Threats
- Competition from larger pharmaceutical distributors in Hangzhou poses a risk.
- Regulatory changes in China's healthcare sector may impact drug distribution.
- Economic downturns could reduce demand for non-essential pharmaceutical products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.